AGE: 10 to 17 | DURATION: 104 weeks | REIMBURSMENT: $100 USD per visit

A 26-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, PHASE 3 TRIAL WITH A 26-WEEK SAFETY EXTENSION PERIOD EVALUATING THE SAFETY AND EFFICACY OF DAPAGLIFOZIN 4 AND 10 MG, AND SAFAGLIPTIN 2.5 AND 5 MG IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE BETWEEN 10 AND BELOW 18 YEARS OF AGE.